Table 5.
Multivariate analysis of factors associated with PFS or OS (landmark analysis).
| PFS | OS | |||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| irAEs (grade 1/2 vs. grade 3/4 or no irAEs) | 0.312 (0.143-0.680) | .003 | 0.081 (0.011-0.614) | .015 |
| ECOG status (0 vs. 1 or 2) | 0.448 (0.246-0.816) | .009 | 0.461 (0.216-0.981) | .044 |
| Child-Pugh class (A vs. B) | 0.479 (0.218–1.052) | .067 | 0.433 (0.170-1.103) | .079 |
| Macrovascular invasion (yes vs. no) | 2.537 (1.418-4.538) | .002 | 2.112 (0.937-4.759) | .071 |
| AFP (<400 ng/mL vs. ≥400 ng/mL) | 0.522 (0.313-0.870) | .013 | 0.422 (0.218–0.818) | .011 |
| Line of therapy (first-line vs. ≥second-line) | 0.669 (0.409-1.094) | .109 | 0.787 (0.394-1.572) | .498 |
Abbreviations: irAE, immune-related adverse event; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoprotein.